SR - 2508：一种2 - 硝基咪唑酰胺，作为临床用放射增敏剂应优于米索硝唑。 - Suppr

SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.

作者信息

Brown J M, Yu N Y, Brown D M, Lee W W

出版信息

Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):695-703. doi: 10.1016/0360-3016(81)90460-0.

DOI:10.1016/0360-3016(81)90460-0

PMID:6457018

Abstract

摘要

相似文献

SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.

Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):695-703. doi: 10.1016/0360-3016(81)90460-0.

[Studies in radiosensitizing effects of misonidazole and SR-2508 on experimental animal tumors].

Nihon Igaku Hoshasen Gakkai Zasshi. 1983 Feb 25;43(2):370-6.

KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

Cancer Chemother Pharmacol. 1990;26(2):112-6. doi: 10.1007/BF02897255.

The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508.

Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):431-4. doi: 10.1016/0360-3016(82)90654-x.

[Radiosensitizer: hypoxic cell radiosensitizer].

Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 2-2):1399-404.

[Recent advances in hypoxic cell radiosensitizer].

Gan No Rinsho. 1983 Oct;29(13):1608-12.

Radiosensitization in vitro and in vivo by 3-nitrotriazoles.

Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1063-6. doi: 10.1016/0360-3016(86)90226-9.

Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.

Int J Radiat Oncol Biol Phys. 1992;22(3):557-60. doi: 10.1016/0360-3016(92)90875-i.

Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170).

Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):575-81. doi: 10.1016/0360-3016(89)90109-0.

A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.

Jpn J Cancer Res. 1989 Nov;80(11):1113-8. doi: 10.1111/j.1349-7006.1989.tb02267.x.

引用本文的文献

An Analysis of the Radiosensitiser Applications in the Biomedical Field.

Curr Radiopharm. 2025;18(2):81-99. doi: 10.2174/0118744710269842240825160247.

Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.

Molecules. 2023 May 31;28(11):4457. doi: 10.3390/molecules28114457.

Hypoxia-targeted drug delivery.

Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a.

The Radiation Stress Response: Of the People, By the People and For the People.

Radiat Res. 2017 Feb;187(2):129-146. doi: 10.1667/RR0CNC.1. Epub 2017 Jan 24.

Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy.

Radiat Oncol J. 2016 Dec;34(4):239-249. doi: 10.3857/roj.2016.02012. Epub 2016 Dec 28.

A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.

Br J Cancer. 2003 Jan 27;88(2):307-13. doi: 10.1038/sj.bjc.6600667.

THNLA-1 as radio/chemosensitiser of EMT-6 tumours in mice.

Br J Cancer Suppl. 1996 Jul;27:S267-70.

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

Br J Cancer. 1993 Oct;68(4):756-66. doi: 10.1038/bjc.1993.424.

Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Cancer Chemother Pharmacol. 1981;6(1):39-49. doi: 10.1007/BF00253009.

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Br J Cancer. 1982 Jul;46(1):109-16. doi: 10.1038/bjc.1982.172.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献